HOME         WEBSITE         SUBSCRIBE           E-GREETINGS   
                               

Tuesday, November 16, 2010

Weekly Scenario: Pharma Fund Gains

The aftermath of the festive season proved costly for investors as global cues, weak domestic industrial growth numbers for September and mixed earnings reports trashed the indices this week. Pullout by foreign institutional investors also weighed on the markets. The IIP growth for the month of September 2010 was at 4.4% (yoy), was quite below the market expectation of 6.4%. The main reason for the slowdown in the growth in industrial production is fall in capital goods index. Sentiments were dampened further by fears that China would increase interest rates to further cool inflation, sparkling a rally in the dollar. 

The fall in equity markets had lead to the fall in NAV of all major equity fund categories while pharma funds gained 1.12%. In the major equity fund category, NAV of Index Funds declined the most by 3.37%, Tax Savings Funds by 2.61% and Equity Diversified Funds by 2.42% during the one week period ended 12 November 2010. Among the sub categories in debt fund, Ultra Short Term Funds surged up 0.14%, Floating Rate Income Funds – Short Term and Liquid Funds surged up 0.13% each. In the ETF category, Gold ETFs gained 2.57% while Other ETFs declined 3.89%. 

Among the sub categories in the hybrid funds, NAV of Debt Oriented Balanced Fund surged by 1.35%, followed by Arbitrage Funds (0.15%). While Equity Oriented Balanced Fund and Monthly Income Plans declined 1.73% and 0.38% respectively. 

Sector Funds
 
Pharma Fund was the lone gainer among the sectoral fund categories. NAV of Pharma Funds category advanced 1.12%, with UTI Pharma & Healthcare Fund ending the week as the biggest gainer with an increase in NAV by 1.92%; it was followed by SBI Magnum SFU – Pharma Fund which gained 1.41%. 

Debt Funds
 
Among the Debt funds, Canara Robeco InDiGo Fund gained 0.68%, HSBC Ultra Short Term Bond Fund added 0.18%, L&T Gilt Investment Plan and Escorts Floating Rate Fund surged 0.17% each. On the flipside Axis Income Saver and SBI Magnum Gilt Fun – Long Term ended at the bottom of the category declining 0.75% and 0.44% respectively. 

Equity Diversified Funds
 
Among the schemes in the equity diversified category, Tata Life Science & Technology Fund, SBI Magnum SFU – Emerging Businesses Fund, Tata Growing Economies Infrastructure – Plan A, Reliance Long Term Equity Fund were the gainers while the rest ended as losers. Their NAV advanced by 0.67%, 0.51%, 0.27% and 0.13% respectively over one week time period. Bharti AXA Focused Infrastructure Fund and SBI PSU Fund ended at the bottom this category declining 4.07% and 4.01% respectively. 

Tax Savings Funds 
 
Escorts Tax Plan and ICICI Pru Tax Plan were able to limit their loss to 0.56% and 1.72% respectively over one week time period. On the other hand Baroda Pioneer ELSS '96 and Bharti AXA Tax Advantage Fund were the worst hit in the tax savings fund category declining 3.86% and 3.51% respectively. 

Index Funds
 
The NAV of Index Fund category declined by 3.37% over one week period with Reliance Index Fund – Sensex, LICMF Index Fund – Sensex Plan being the top losers in this category. Their returns declined 3.65% and 3.57% respectively over one week time period. 

Hybrid Funds
 
Escorts Income Bond was the highest gainer in debt oriented balanced fund category as its NAV appreciated by 29.62%. DWS Money Plus Advantage Fund was the next highest gainer by 0.59%. Templeton India Pension Plan and Tata Young Citizens Fund were the worst performers in this category with a decline in NAV by 1.23% and 1.19% respectively.
HDFC Arbitrage Fund and Reliance Arbitrage Advantage Fund were the highest gainers in arbitrage fund category as their NAV appreciated by 0.23% and 0.21% respectively.

Blog Archive

____________________________________________________________________________________________

Disclaimer - All investments in Mutual Funds and securities are subject to market risks and uncertainty of dividend distributions and the NAV of schemes may go up or down depending upon factors and forces affecting securities markets generally. The past performance of the schemes is not necessarily indicative of the future performance and may not necessarily provide a basis for comparison with other investments. Investors are advised to go through the respective offer documents before making any investment decisions. Prospective client(s) are advised to go through all comparable products in offer before taking any investment decisions. Mutual Funds and securities investments are subject to market risks and there is no assurance or guarantee that the objectives of the fund will be achieved. Information gathered & material used in this document is believed to be from reliable sources. Decisions based on the information provided on this newsletter/document are for your own account and risk.


In the preparation of the material contained in this document, Varun Vaid has used information that is publicly available, including information developed in-house. Some of the material used in the document may have been obtained from members/persons other than the Varun Vaid and which may have been made available to Varun Vaid. Information gathered & material used in this document is believed to be from reliable sources. Varun Vaid however does not warrant the accuracy, reasonableness and/or completeness of any information. For data reference to any third party in this material no such party will assume any liability for the same. Varun Vaid does not in any way through this material solicit any offer for purchase, sale or any financial transaction/commodities/products of any financial instrument dealt in this material. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice.


Varun Vaid, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. All recipients of this material should before dealing and/or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. Any person subscribing to or investigating in any product/financial instruments should do soon the basis of and after verifying the terms attached to such product/financial instrument. Financial products and instruments are subject to market risks and yields may fluctuate depending on various factors affecting capital/debt markets. Please note that past performance of the financial products and instruments does not necessarily indicate the future prospects and performance there of. Such past performance may or may not be sustained in future. Varun Vaid, including persons involved in the preparation or issuance of this material may; (a) from time to time, have long or short positions in, and buy or sell the securities mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation in the financial instruments/products/commodities discussed here in or act as advisor or lender / borrower in respect of such securities/financial instruments/products/commodities or have other potential conflict of interest with respect to any recommendation and related information and opinions. The said person may have acted upon and/or in a manner contradictory with the information contained here. No part of this material may be duplicated in whole or in part in any form and or redistributed without the prior written consent of Varun Vaid. This material is strictly confidential to the recipient and should not be reproduced or disseminated to anyone else.


Varun Vaid also does not take any responsibility for the contents of the advertisements published. Readers are advised to verify the contents on their own before acting there upon.


Published Credits goes to following sources & all the mentioned sources as footer below the published material- Bloomberg, Valueresearch Online, Capital Market, Navindia, Franklin Templeton, Kitco, SBI AMC, LIC AMC, JM Financial AMC, HDFC AMC, The Hindu, Business Line, Personal FN, Economic Times, Reuters, Outlook Money, Business Standard, Times of India etc.